Clinical Trials Browser

Phase 2 × IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy × Pemetrexed × Clear all

NCT04316351 2020-07-23

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

Phase 2 Unknown

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy